438 related articles for article (PubMed ID: 17934353)
1. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic complications of angiogenesis inhibitors in cancer patients.
Elice F; Jacoub J; Rickles FR; Falanga A; Rodeghiero F
Am J Hematol; 2008 Nov; 83(11):862-70. PubMed ID: 18819092
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic events in patients with cancer receiving antiangiogenesis agents.
Zangari M; Fink LM; Elice F; Zhan F; Adcock DM; Tricot GJ
J Clin Oncol; 2009 Oct; 27(29):4865-73. PubMed ID: 19704059
[TBL] [Abstract][Full Text] [Related]
4. [Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].
Drouet L
Pathol Biol (Paris); 2008 Jun; 56(4):195-204. PubMed ID: 18450388
[TBL] [Abstract][Full Text] [Related]
5. Thrombosis associated with angiogenesis inhibitors.
Elice F; Rodeghiero F; Falanga A; Rickles FR
Best Pract Res Clin Haematol; 2009 Mar; 22(1):115-28. PubMed ID: 19285278
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents.
Perry JR
Curr Opin Neurol; 2010 Dec; 23(6):592-6. PubMed ID: 20881488
[TBL] [Abstract][Full Text] [Related]
7. Thrombosis in multiple myeloma.
Zangari M; Elice F; Fink L; Tricot G
Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparins and angiogenesis.
Norrby K
APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
[TBL] [Abstract][Full Text] [Related]
9. Side effects of anti-angiogenic drugs.
Elice F; Rodeghiero F
Thromb Res; 2012 Apr; 129 Suppl 1():S50-3. PubMed ID: 22682133
[TBL] [Abstract][Full Text] [Related]
10. Clinical studies with anticoagulants to improve survival in cancer patients.
Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I
Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993
[TBL] [Abstract][Full Text] [Related]
11. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact.
Elice F; Rodeghiero F
Thromb Res; 2010 Apr; 125 Suppl 2():S55-7. PubMed ID: 20434006
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of anti-angiogenesis therapy: update for the internist.
Gurevich F; Perazella MA
Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
[TBL] [Abstract][Full Text] [Related]
15. Combining radiotherapy and angiogenesis inhibitors: clinical trial design.
Citrin D; Ménard C; Camphausen K
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):15-25. PubMed ID: 16377411
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotics in thrombosis and cancer.
Mousa SA
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):283-91. PubMed ID: 15030287
[TBL] [Abstract][Full Text] [Related]
17. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
18. Vascular damaging agents.
Patterson DM; Rustin GJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulants in thrombosis and cancer: the missing link.
Mousa SA
Expert Rev Anticancer Ther; 2002 Apr; 2(2):227-33. PubMed ID: 12113244
[TBL] [Abstract][Full Text] [Related]
20. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
Själander A; Wallentin L; Rosenqvist M; Svensson P
Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
